Education
1994.09~1999.07 Bachelor in medicine, Tianjin Medical University
1999.09~2002.07 Master in pathology, Tianjin Medical University
2002.09~2007.07 Ph.D in oncology, Tianjin Medical University
Professional Experiences
2002.07~2006.05 Resident, Department of Pathology, Tianjin Medical University Cancer Institute&Hospital
2005.02~2006.09 Visiting scholar/PhD candidate, State Key Laboratory of Molecular Oncology, Institute of Oncology, Chinese Academy of Medical Sciences
2006.06~2009.09 Attending physician, Department of Pathology, Tianjin Medical University Cancer Institute&Hospital
2009.10~2014.12 Associate chief physician, Department of Pathology, Tianjin Medical University Cancer Institute&Hospital
2010.05~2012.01 Visiting scholar/postdoctoral fellow, Department of pathology and microbiology, Nebraska medical center, Nebraska, USA
2011.04~present Master tutor, Tianjin Medical University
2013.06~present Class II PI, Tianjin Medical University Cancer Institute&Hospital
2014.12~present Chief physician, Department of Pathology, Tianjin Medical University Cancer Institute&Hospital
Research Focus
(1).Epithelial splicing regulatory protein 1 (ESRP1) is an RNA RBP.ESRP1 regulates epithelial-specific splicing of the IgIII of fibroblast growth factor receptor (FGFR) 2 and generates the FGFR IIIb or the FGFR IIIc isoforms. FGFR IIIb is down-regulated during EMT, whereas FGFR IIIc is up-regulated to confer sensitivity to FGF2, thus inducing even more aggressive phenotypes. In our study, we demonstrate that the downexpression of ESRP1 promotes the invasion and metastasis of lung ADC. ZEB1, a transcription factor, may regulate ESRP1 promoter transcriptional activity during EMT.
(2).Our study found that Nonsense-mediated mRNA decay (NMD)core factor UP-frameshift 1 tends to be expressed at lower levels in human ADC tissues than in normal lung tissues, Our experiments showed that downregulating NMD can promote EMT. Moreover, EMT can be inhibited by upregulating NMD. We found that NMD influences EMT by targeting the TGF-ß signaling pathway in lung ADC cells.
(3).Used clinicopathological criteria and whole exome sequencing (WES) to distinguish between synchronous endometrial and ovarian cancer and metastatic single primary tumors.
(4).To explore the specific role of ISG15 in lung adenocarcinoma and to clarify the specific mechanism of action of ESRP1 in regulating ISG15 expression and localization.
Selected Publications